TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Evaluating the Safety and Effectiveness of Decitabine in People With Thalassemia Intermedia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Beta-thalassemia and beta thalassemia-hemoglobin E (HbE), as confirmed by DNA testing~* Transfusion independent for at least 120 days before study entry~* Red blood cell folate levels above the lower limit of normal~Exclusion Criteria:~* Absolute neutrophil count (ANC) less than 2000/mm3 in the 8 weeks before study entry or a history of chronic neutropenia, defined as an ANC less than 2000/mm3~* Platelet count less than 100,000/mm3 or greater than 1,000,000/mm3 in the 8 weeks before study entry~* Family history of an inherited disease resulting in low ANC or bone marrow failure~* Serum creatinine level greater than 2 mg/dL in the 8 weeks before study entry~* Evidence of liver disease, as defined by one or more of the following conditions:~  1. Alanine aminotransferase (ALT) level greater than 3 times the upper limit of normal in the 8 weeks before study entry~ 2. Serum albumin level less than 3 g/dL in the 8 weeks before study entry~ 3. Evidence of cirrhosis on liver biopsy obtained in the 6 months before study entry~* Approaching death; has concurrent liver, kidney, cardiac, or metabolic disease; or has any disease of such severity that death within 7 to 10 days of study entry is likely~* Pregnant, planning to become pregnant, or breastfeeding~* Sexually active female of childbearing potential who is unwilling to use at least two acceptable methods of contraception, as determined by the investigator~* Sexually active male whose partner is of child-bearing potential and who is unwilling to use at least two acceptable methods of contraception, as determined by the investigator, during and for 2 months after decitabine treatment~* Diagnosed with cancer (except non-melanoma skin cancer) in the 5 years before study entry. In particular, suspicion or evidence of myelodysplastic syndrome (MDS) on clinically indicated bone marrow aspirate or a family history of MDS or concurrent leukemia~* HIV infection~* Not expected to be able to complete 24 weeks of study follow-up~* Currently being treated with any experimental or fetal hemoglobin modulating agent~* Current participation in any other studies of investigational drugs or devices~* Unable to comply with study medication regimen~* Any condition, which in the opinion of the investigator, would place the individual at undue risk if treated with twice-weekly low-dose decitabine for 12 weeks

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Participants will receive injected decitabine for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Performance Status During Treatment With Pemetrexed in Patients With NSCLC

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Are 18 years of age or older~* Have NSCLC, Stage IIIa/b or IV, that is not amenable to curative therapy~* Have had one prior chemotherapy regimen with cytotoxic agents for the treatment of NSCLC (patients with adjuvant and neoadjuvant regimens are also eligible. However, patients with one prior cytotoxic chemotherapy followed by a targeted agent such as erlotinib are not eligible because the targeted agent would be regarded as second-line treatment)~* Are initiating second-line of treatment for NSCLC with pemetrexed~* Have been fully informed and have given written consent for the use of their data.~Exclusion Criteria:~* Have received any prior treatment with pemetrexed~* Are participating in a study including administration of any investigational drug or procedure at entry into this study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Second-line pemetrexed treatment in NSCLC (Type: None): Patients with NSCLC who will start second-line treatment with pemetrexed.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Efficacy and Safety of a 3-month Treatment Course of Ulipristal Acetate for the Treatment of Abnormal Uterine Bleeding Associated With Leiomyomas

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Pre-menopausal women, 18-50 years, inclusive.~* Cyclic abnormal uterine bleeding (heavy or prolonged).~* Menstrual blood loss (MBL) of ≥ 80 mL as measured by the alkaline hematin method in the first 8 days of menses.~* Minimum of one discrete leiomyoma observable by transvaginal ultrasound.~* Endometrial biopsy without evidence of malignancy or atypical or non-atypical hyperplasia~Exclusion Criteria:~* History of uterine surgery that would interfere with the study endpoints.~* Known coagulation disorder including bleeding disorder or clotting disorder.~* History of, or current uterine, cervix, ovarian, or breast cancer.~* Alanine transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP), or total bilirubin two times or greater than the upper limit of normal rang

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- UPA 5 mg (Type: EXPERIMENTAL): Ulipristal acetate (UPA) 5 mg tablet plus matching placebo 10 mg tablet, orally, once daily for 12 weeks.
- UPA 10 mg (Type: EXPERIMENTAL): UPA 10 mg tablet plus matching placebo 5 mg tablet, orally, once daily for 12 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo tablets (5 mg and 10 mg), orally, once daily for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Fixed Dose Combination Drug (Polypill)for Secondary Cardiovascular Prevention.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Phase 1: All patients, male and female, 40 years of age or older, with a history of ST-elevation AMI within the last 2 years, attending any of the selected sites and signing the consent~* Phase 2: All patients, male and female, 40 years of age or older, with a history of ST-elevation AMI within the last 2 years, attending any of the selected sites and signing the consent Patients in whom secondary prevention with ASA, statin and ACEI is indicated, Signing informed consent~Exclusion Criteria:~* Phase 1: Patients in which any of the components of the FDC is contraindicated. Living in a nursing home. Memtal illness limiting the capacity of~* Phase 2:Secondary dyslipemia, Patients in which any of the components of the FDC is contraindicated, Living in a nursing home, Mental illness limiting the capacity of self care, Participating in another trial, , Previous Percutaneous Transluminal Coronary Angioplasty (PTCA) with a drug eluting stent (DES) whitin the last year, Severe Congestive Heart Failure (NYHA III-IV), Serum creatinine \>2 mg/dl, any condition limiting life expectancy \<2 years. Pregnant or premenopausal women.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- FDC Fixed Dose Combination (Type: EXPERIMENTAL): None
- Conventional treatment (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: PRIME: Pilot Study Evaluating Percutaneous Vaccination of BCG for Bladder Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~The patient must:~* Be 18 years of age or older~* Be able to give informed consent~* Have newly diagnosed or recurrent multi-focal Ta, Large Ta, High Grade Ta, CIS or T1 Bladder Cancer~* Determined by treating urologist to be a good candidate for BCG Induction Therapy~* Have an adequate marrow function (defined as white blood cells greater than 1.5 x 103/µl (or 1,500 cells/mm3) and platelets greater than 150,000 cells/mm3; these results can be within last 60 days from the day of signing informed consent~Exclusion Criteria:~The patient cannot:~* Be less than18 years of age~* Unable to give informed consent~* Have a history of muscle invasive bladder cancer~* Be self-reported to be immune-compromised (HIV, chronic immunomodulators, chronic corticosteroids)~* Have a history of tuberculosis and/or received BCG Percutaneous Vaccination~* Pregnant or planning to become pregnant.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: t

Study Arms:
- non-muscle invasive bladder cancer (Type: EXPERIMENTAL): Every patient meeting eligibility criteria will receive a standard WHO adult potency Bacillus Calmette-Guerin (BCG) immunization (1cc/50mg live mycobacilli) in the right or left deltoid. Following a 19 - 31day wait period after BCG vaccination patients will then receive standard strength BCG intravesical therapy returning once a week for 6 consecutive weeks. Cystoscopy will be performed at 3 and 6 months.~Interventions: BCG immunization in deltoid and BCG intravesical therapy once a week for 6 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of BGB-A317 in Participants With Previously Treated Unresectable HCC

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Histologically confirmed HCC~2. Participants with Barcelona Clinic Liver Cancer (BCLC) Stage C, or BCLC stage B not amenable to locoregional therapy or relapsed after locoregional therapy, and not amenable to a curative treatment approach~3. Has received at least 1 line of systemic therapy for unresectable HCC~4. Has at least 1 measurable lesion as defined per RECIST v1.1~5. Child-Pugh score A~6. Easter Cooperative Oncology Group (ECOG) Performance Status ≤ 1~7. Adequate organ function~Key Exclusion Criteria:~1. Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC histology~2. Prior therapies targeting PD-1 or PD-L1~3. Has known brain or leptomeningeal metastasis~4. Tumor thrombus involving main trunk of portal vein or inferior vena cava~5. Loco-regional therapy to the liver within 4 weeks before enrollment~6. Medical history of interstitial lung disease, non-infectious pneumonitis or uncontrolled systemic diseases, including diabetes, hypertension, pulmonary fibrosis, or acute lung diseases~7. Has received:~   1. Within 28 days or 5 half-lives (whichever is shorter) of the first study drug administration: any chemotherapy, immunotherapy (eg, interleukin, interferon, thymoxin) or any investigational therapies~  2. Within 14 days of the first study drug administration: sorafenib, regorafenib, or any Chinese herbal medicine or Chinese patent medicines used to control cancer~8. Active autoimmune diseases or history of autoimmune diseases that may relapse~9. Participant with any condition requiring systemic treatment with either corticosteroids (\> 10 mg daily of prednisone or equivalent) or other immunosuppressive medication within 14 days before study drug administration~NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tislelizumab (Type: EXPERIMENTAL): 200 milligrams once every 3 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Effectiveness and Safety of Paliperidone Palmitate in Subjects With Acute Schizophrenia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Have a current diagnosis of schizophrenia as defined by Diagnostic and Statistical Manual of Mental Disorders Version IV (DSM-IV)~* Must be admitted to a hospital within 4 weeks prior to Screening experiencing an acute exacerbation of schizophrenia~* Have a positive and negative syndrome scale (PANSS) total score of more than or equal to 60 or clinical global impressions - severity (CGI-S) score of more than or equal to 4 (moderately ill) at Screening~* Agree to protocol-defined method of contraception~* Must be medically stable based on physical examination, medical history, vital signs, and clinical laboratory tests performed at Screening~Exclusion Criteria:~* Have a primary active DSM-IV Axis I diagnosis other than schizophrenia~* Have evidence of clinically significant cardiovascular, renal, hepatic, gastrointestinal, neurological, endocrine, metabolic or pulmonary disease in medical history, clinical laboratory or physical examination~* Have a history of neuroleptic malignant syndrome~* Participants at risk of suicide~* Have received clozapine within 1 month prior to Screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Paliperidone palmitate (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ability of Caregivers to Provide Ventilation With the SAVe Resuscitator in a Model

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Voluntary participation~* Nurse, respiratory therapist, or physician~* involved in the care of patients requiring ventilation and airway management~Exclusion Criteria:~-

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Hold Mask (Type: ACTIVE_COMPARATOR): The clinician will connect a SAVe ventilator to a face mask and hold the mask in place on the mannequin with two hands while maintaining the airway on the correct position for 10 minutes.
- Strap Mask (Type: ACTIVE_COMPARATOR): The clinician will attach the face mask to the mannequin using the mask and mask strap included in the ventilator kit for 10 minutes
- Airway (Type: ACTIVE_COMPARATOR): The clinician will blindly insert a supralaryngeal airway (the King lT) and connect the SAVe ventilator to the connector and provide ventilation for 10 minutes.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Continuation Study of Herceptin (Trastuzumab) in Participants With Metastatic or Locally Advanced Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Ongoing participants from any completed global Roche-sponsored Herceptin trial~* Participants enrolled in any Roche-sponsored Herceptin trial who have at least stable disease (or whose disease has not recurred) during Herceptin therapy at the end of the lead-in trial~* Available study termination data (including tumor assessment and laboratory data) on the Case Report Form for the lead-in trial~* Judged eligible by the investigator following a thorough risk/benefit assessment, if signs of chronic heart failure developed during the lead-in trial~Exclusion Criteria:~* Pregnant or nursing women~* Women of childbearing potential unless using effective contraception as determined by the investigator~* Severe dyspnea at rest requiring supplementary oxygen therapy~* Severe uncontrolled systemic disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Herceptin (Type: EXPERIMENTAL): Participants with stable disease and HER2-overexpressing metastatic or locally advanced cancer will receive expanded access to IV Herceptin until disease progression, unacceptable toxicity, death, or decision by the investigator or participant to discontinue treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~(Patient should meet all the criteria)~* JAK2V617F-positive PV or JAK2V617F-positive ET (confirmed by WHO diagnostic criteria)~* High risk ET/PV \[age \>60; history of thrombosis\] or low risk disease with symptoms \[recurrent headaches, paresthesias, pruritus\]~* Previously treated with at least one other agent \[hydroxyurea, interferon, anagrelide\] and determined to be either intolerant/resistant~  -≥18 years of age~* Eastern Cooperative Oncology Group (ECOG) Performance status 0-2~* Acceptable pre-study organ function during screening as defined as: Total bilirubin ≤ 1.5 times the upper limit of normal (ULN) unless due to Gilbert's disease or hemolysis, Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 times ULN, Serum creatinine ≤ 1.5 x ULN~* Women of childbearing potential and males must agree to use adequate contraception (i.e., hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a female subject become pregnant or suspect she is pregnant while participating in this study, she should inform the treating physician immediately~* Ability to understand and willingness to sign a written informed consent document.~Exclusion Criteria:~* Meets the criteria for post ET/PV MF as defined by the International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT)~* Blast phase disease (\>20% blasts in the marrow or peripheral blood)~* Acute thrombosis within 3 months of screening~* Uncontrolled intercurrent illness including, but not limited to hepatitis, human immunodeficiency virus (HIV) - positive subjects receiving combination antiretroviral therapy, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, ventricular arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- RG7388 (Type: EXPERIMENTAL): Part A: RG7388 as a single agent; given at a starting dose of 100 mg each day for five days for the first cycle which will be 56 days.~Part B: combination of RG7388 and Pegasys if subject does not achieve at least a PR by the end of 3 cycles of single agent RG7388

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Orally Disintegrating Selegiline in Parkinson's Patients Experiencing Adverse Effects With Dopamine Agonists

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Idiopathic Parkinson's disease (PD) confirmed by at least two of the following signs: resting tremor, bradykinesia,rigidity~* Male or female outpatients~* Age 30-90 years~* Current use of levodopa (stable for at least 1 month) and a dopamine agonist (pramipexole or ropinirole)~* Treatment response to current anti-parkinsonian medications in the opinion of the investigator~* Dopamine agonist adverse effect that in the opinion of the investigator requires a reduction or discontinuation of the dopamine agonist. The adverse effects must be in one of the following four categories and should not be so severe as to require immediate discontinuation of the dopamine agonist (i.e., hallucinations without insight, serious impulsive behavior resulting in significant loss or danger to the patient).~Daytime sleepiness - must score \>10 on Epworth Sleepiness Scale (ESS) at Baseline; Pedal edema - bothersome/concerning to patient; Hallucinations - insight should be maintained; Impulsive behavior - not including behaviors that are harmful to the patient requiring immediate discontinuation of the agonist.~* Daily off time~* Acceptable contraception for females of child bearing potential~* Willing and able to comply with study procedures.~* Willing and able to give written informed consent prior to beginning any study procedures.~Exclusion Criteria:~* Atypical parkinsonism due to drugs, metabolic disorders, encephalitis, trauma, or other neurodegenerative diseases.~* Significant cognitive or psychiatric impairment which, in the opinion of the investigator, would interfere with the ability to complete all the tests required in the protocol.~* Participation in another clinical drug trial within the previous four weeks.~* Patients currently on monoamine oxidase type A or B (MAO-A or B) inhibitors, meperidine, tramadol, methadone, propoxyphene, dextromethorphan, and mirtazapine.~* History of hypersensitivity or adverse reaction to selegiline or previous exposure to orally disintegrating selegiline~* History of melanoma~* Unstable/uncontrolled medical problems~* History of drug/alcohol abuse

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- orally disintegrating selegiline (Type: OTHER): This is a one arm open label study of patients who are experiencing a dopamine agonist (DA) related adverse effects (AE) of either one or more of the following: excessive daytime sleepiness, hallucinations, pedal edema, impulse control disorder. All subjects received orally disintegrating selegiline.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete